AVID200
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Scleroderma, Diffuse
Conditions
Scleroderma, Diffuse
Trial Timeline
Jan 1, 2019 → Jun 20, 2020
NCT ID
NCT03831438About AVID200
AVID200 is a phase 1 stage product being developed by Bristol Myers Squibb for Scleroderma, Diffuse. The current trial status is completed. This product is registered under clinical trial identifier NCT03831438. Target conditions include Scleroderma, Diffuse.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03834662 | Phase 1 | Completed |
| NCT03831438 | Phase 1 | Completed |
Competing Products
15 competing products in Scleroderma, Diffuse
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| Cuprimine (penicillamine) | Merck | Pre-clinical | 23 |
| rapcabtagene autoleucel + rituximab | Novartis | Phase 2 | 52 |
| STI571 | Novartis | Phase 2 | 52 |
| Imatinib mesylate | Novartis | Phase 2 | 52 |
| imatinib mesylate | Novartis | Phase 2 | 52 |
| Mycophenolate mofetil | Roche | Pre-clinical | 23 |
| Mycophenolate mofetil + Cyclophosphamide + Placebo | Roche | Phase 2 | 52 |
| Fludarabine + Cyclophosphamide + Thymoglobulin | Amgen | Phase 1 | 32 |
| BMS-986020 | Bristol Myers Squibb | Phase 2 | 51 |
| dasatinib | Bristol Myers Squibb | Phase 1/2 | 40 |
| Abatacept + Placebo | Bristol Myers Squibb | Phase 1/2 | 40 |
| Rilonacept | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| Riociguat + Placebo | Bayer | Phase 2 | 49 |
| Riociguat (Adempas, BAY63-2521) + Placebo | Bayer | Phase 2 | 49 |